Another Option for Hypoactive Sexual Desire

The FDA recently approved bremelanotide for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It ’s the first “as-needed” treatment for HSDD, a common condition characterized by low libido that causes distress or interpersonal difficulty and isn’t attributed to a coexisting medical or psychiatric condition, relationship problems, or medications.
Source: JAMA - Category: General Medicine Source Type: research